The identification of the signaling components that break down in the early stages of Alzheimer's and Parkinson's disease will allow us to develop tailored treatments for these conditions. Most of the current research on AD and PD is focused on reversing the pathological changes in the late stages of these conditions, when significant neuronal loss had occurred. In contrast, the treatments we strive to develop are focused on restoring the normal signaling and integrity of the brain network at early stages of these conditions when only the sense of smell is affected and cognition and memories are still intact. 


        

---